Saturday 17 October 2026
Export OLMA’s income statement to Excel — free account
Olema Pharmaceuticals, Inc.
OLMA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 19.6%, free cash flow fell 54.3% and total debt was flat, each against the same quarter a year earlier.
6.58
0.29
−4.22%
Follow OLMA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(59.22%) | (36.61%) | (42.86%) | (52.74%) | |
| (51.48%) | (33.00%) | (39.38%) | (47.10%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(51.24%) | (35.04%) | (39.73%) | (49.07%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.57) | (1.69) | (1.45) | (1.58) | |
Free Cash Flow |
(134.67) | (146.72) | (148.72) | (164.96) | |
Capital Expenditures |
— | — | — | (0.23) | |
| Other line items | |||||
Cash ROIC |
(21.06%) | (14.86%) | (15.04%) | (18.44%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.90 | 0.90 | 0.80 | 0.81 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.50) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.57) | (1.69) | (1.45) | (1.58) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates